Kendall Capital Management Purchases Shares of 8,362 Gilead Sciences, Inc. $GILD

Kendall Capital Management purchased a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 8,362 shares of the biopharmaceutical company’s stock, valued at approximately $1,056,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in GILD. BlackRock Inc. bought a new position in shares of Gilead Sciences in the second quarter valued at $15,393,785,000. Norges Bank acquired a new position in Gilead Sciences during the fourth quarter worth $2,617,152,000. Deutsche Bank AG bought a new stake in Gilead Sciences during the second quarter worth $918,387,000. Boston Partners bought a new stake in Gilead Sciences during the fourth quarter worth $517,808,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in Gilead Sciences in the second quarter valued at $398,905,000. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Stock Performance

NASDAQ GILD opened at $146.12 on Friday. The firm has a 50-day moving average of $131.97 and a 200-day moving average of $136.59. The company has a debt-to-equity ratio of 2.03, a quick ratio of 1.09 and a current ratio of 1.27. The stock has a market cap of $181.18 billion, a PE ratio of -54.73 and a beta of 0.32. Gilead Sciences, Inc. has a 52-week low of $108.46 and a 52-week high of $157.29.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) EPS for the quarter, topping the consensus estimate of ($7.25) by $0.50. The business had revenue of $7.80 billion during the quarter, compared to the consensus estimate of $7.40 billion. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. Gilead Sciences’s revenue was up 10.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.01 EPS. On average, sell-side analysts anticipate that Gilead Sciences, Inc. will post -0.51 EPS for the current year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 29th. Stockholders of record on Tuesday, September 15th will be given a $0.82 dividend. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $3.28 annualized dividend and a dividend yield of 2.2%. Gilead Sciences’s dividend payout ratio is presently -122.85%.

Insider Transactions at Gilead Sciences

In related news, Director Jeffrey Bluestone sold 5,000 shares of the business’s stock in a transaction on Thursday, August 20th. The stock was sold at an average price of $145.02, for a total value of $725,100.00. Following the completion of the sale, the director directly owned 10,066 shares in the company, valued at $1,459,771.32. The trade was a 33.19% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 28,000 shares of the company’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $137.64, for a total value of $3,853,920.00. Following the completion of the transaction, the insider directly owned 118,234 shares in the company, valued at approximately $16,273,727.76. This represents a 19.15% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 87,000 shares of company stock worth $11,562,960 over the last three months. Company insiders own 0.30% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on GILD shares. Leerink Partners downgraded shares of Gilead Sciences from an “outperform” rating to a “market perform” rating and decreased their price objective for the company from $146.00 to $127.00 in a research report on Tuesday, July 21st. Maxim Group upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 target price for the company in a research note on Wednesday, May 20th. Truist Financial reduced their price target on Gilead Sciences from $157.00 to $156.00 and set a “buy” rating for the company in a report on Tuesday, July 7th. Wall Street Zen upgraded Gilead Sciences from a “hold” rating to a “buy” rating in a report on Saturday, August 15th. Finally, Morgan Stanley dropped their price objective on Gilead Sciences from $166.00 to $165.00 and set an “overweight” rating on the stock in a research note on Monday, July 27th. Twenty-four equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $158.04.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.